Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Santen Pharmaceutical Co., Ltd. (OTC: SNPHY).

Full DD Report for SNPHY

You must become a subscriber to view this report.


Recent News from (OTC: SNPHY)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines
Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril...
Source: SeekingAlpha
Date: February, 13 2018 12:46
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril...
Source: SeekingAlpha
Date: February, 09 2018 07:54
Santen Pharmaceutical Co., Ltd. ADR 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Santen Pharmaceutical Co., Ltd. ADR in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: February, 06 2018 14:43
ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List
Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril...
Source: SeekingAlpha
Date: February, 06 2018 11:42
ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates
Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril...
Source: SeekingAlpha
Date: February, 02 2018 10:50
ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades
Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril...
Source: SeekingAlpha
Date: January, 30 2018 11:51
Santen Pharmaceutical (SNPHY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
The following slide deck was published by Santen Pharmaceutical Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: January, 09 2018 14:04
Santen Pharmaceutical Co., Ltd. ADR 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Santen Pharmaceutical Co., Ltd. ADR in conjunction with their 2017 Q2 earnings Read more ...
Source: SeekingAlpha
Date: November, 05 2017 11:29
Santen - An Overlooked Play On An Overlooked Space
Ophthalmology doesn't really get much attention from most drug companies, and I suppose I can't blame them - the entire global market is estimated to be worth around $25 billion in 2017 while Celgene's (CELG) cancer drug Revlimid annualizes close to $8 billion in sales alone. In other words,...
Source: SeekingAlpha
Date: March, 10 2017 07:00
Tracon Pharmaceuticals: An Underdog Can Rise Up
Tracon's (NASDAQ: TCON ) quotations have gone down 60% from November to today mainly for two reasons: The issue of new shares and the failure of one of the principal candidate's study. The fact that Tracon has money at its disposal and that there are other upcoming decisive events makes th...
Source: SeekingAlpha
Date: February, 21 2017 11:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1315.23515.1015.3215.099,564
2018-08-1015.1915.3015.3015.193,812
2018-08-0915.4815.3815.51615.383,680
2018-08-0815.6915.58515.6915.536,133
2018-08-0715.6315.6715.74515.6314,905

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-132139,5642.2271Cover
2018-08-09483,6801.3043Cover
2018-08-0710114,9050.6776Cover
2018-08-063673,36810.8967Cover
2018-08-031,0063,97025.3401Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNPHY.


About Santen Pharmaceutical Co., Ltd. (OTC: SNPHY)

Logo for Santen Pharmaceutical Co., Ltd. (OTC: SNPHY)

Not available

 

Contact Information

 

 

Current Management

  • Akira Kurokawa / President, CEO

Current Share Structure

     


    Recent Filings from (OTC: SNPHY)

    Post-effective amendment to a previously filed F-6
    Filing Type: F-6 POSFiling Source: edgar
    Filing Date: September, 29 2017
    Filing to become effective immediately upon filing
    Filing Type: F-6EFFiling Source: edgar
    Filing Date: March, 07 2016

     

     


    Daily Technical Chart for (OTC: SNPHY)

    Daily Technical Chart for (OTC: SNPHY)


    Stay tuned for daily updates and more on (OTC: SNPHY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: SNPHY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNPHY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SNPHY and does not buy, sell, or trade any shares of SNPHY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/